Replimune Group Management
Management criteria checks 3/4
Replimune Group's CEO is Sush Patel, appointed in Apr 2024, has a tenure of less than a year. total yearly compensation is $2.60M, comprised of 17.2% salary and 82.8% bonuses, including company stock and options. directly owns 0.041% of the company’s shares, worth $160.84K. The average tenure of the management team and the board of directors is 0.4 years and 6 years respectively.
Key information
Sush Patel
Chief executive officer
US$2.6m
Total compensation
CEO salary percentage | 17.2% |
CEO tenure | less than a year |
CEO ownership | 0.04% |
Management average tenure | less than a year |
Board average tenure | 6yrs |
Recent management updates
Recent updates
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Replimune: In The 'Buy Zone' Again
Oct 01Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Sep 02Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business
May 24Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
Apr 30We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow
Feb 08Replimune Group EPS misses by $0.03
Feb 04Dosing underway in Replimune's early-stage cancer study with gene therapy
Jan 05Replimune: Interesting Developer Of Oncolytic Immunotherapies
Dec 06Replimune Group EPS misses by $0.02
Nov 05CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$210m |
Sep 30 2023 | n/a | n/a | -US$199m |
Jun 30 2023 | n/a | n/a | -US$182m |
Mar 31 2023 | US$3m | US$447k | -US$174m |
Dec 31 2022 | n/a | n/a | -US$157m |
Sep 30 2022 | n/a | n/a | -US$147m |
Jun 30 2022 | n/a | n/a | -US$133m |
Mar 31 2022 | US$7m | US$394k | -US$118m |
Compensation vs Market: Sush's total compensation ($USD2.60M) is about average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Sush's compensation has been consistent with company performance over the past year.
CEO
Sush Patel (52 yo)
less than a year
Tenure
US$2,595,003
Compensation
Dr. Sushil Patel Ph.D. served as the Chief Commercial Officer at Replimune Group, Inc. since May 3, 2021 and serves as its Chief Strategy Officer. He served as the Head of global oncology for lung cancer,...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 9.3yrs | US$3.65m | 2.1% $ 8.2m | |
Chief Executive Officer | less than a year | US$2.60m | 0.041% $ 160.8k | |
Founder | less than a year | US$5.72m | 2.82% $ 11.0m | |
Chief Financial Officer | less than a year | no data | no data | |
Chief Accounting Officer & Treasurer | less than a year | no data | 0.0046% $ 17.7k | |
Chief Commercial Officer | 1.4yrs | no data | 0.014% $ 54.0k | |
Chief Medical Officer | 1.4yrs | no data | 0.081% $ 314.9k | |
Chief Manufacturing Officer & Framingham Site Head | less than a year | no data | no data |
0.4yrs
Average Tenure
52yo
Average Age
Experienced Management: REPL's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 9.3yrs | US$3.65m | 2.1% $ 8.2m | |
Founder | 9.3yrs | US$5.72m | 2.82% $ 11.0m | |
Independent Director | 6.6yrs | US$255.96k | 0.011% $ 42.3k | |
Independent Non-Executive Director | 6yrs | US$251.96k | 0% $ 0 | |
Independent Director | 4.1yrs | US$251.96k | 0% $ 0 | |
Independent Director | 6.8yrs | US$252.96k | 0% $ 0 | |
Independent Director | 2.4yrs | US$248.46k | no data | |
Independent Chairman of the Board | 5.9yrs | US$371.44k | 0% $ 0 | |
Independent Director | less than a year | no data | no data |
6.0yrs
Average Tenure
58yo
Average Age
Experienced Board: REPL's board of directors are considered experienced (6 years average tenure).